Publications

• Assay-Specific Spurious ACTH Results Lead to Misdiagnosis, Unnecessary Testing, and Surgical Misadventure-A Case Series.

  (Greene LW, Geer EB, Page-Wilson G, Findling JW, Raff H.) J Endocr Soc. 2019 Apr 01;3(4):763-772.

• Continuous Etomidate Infusion for the Management of Severe Cushing Syndrome: Validation of a Standard Protocol.

  (Carroll TB, Peppard WJ, Herrmann DJ, Javorsky BR, Wang TS, Patel H, Zarnecki K, Findling JW.) J Endocr Soc. 2019 Jan 01;3(1):1-12.

• Differentiation of pathologic/neoplastic hypercortisolism (Cushing syndrome) from physiologic/non-neoplastic hypercortisolism (formerly known as Pseudo-Cushing syndrome): response to Letter to the Editor.

  (Findling JW, Raff H.) Eur J Endocrinol. 2018 03;178(3):L3.

• A Multi-institutional Comparison of Adrenal Venous Sampling in Patients with Primary Aldosteronism: Caution Advised if Successful Bilateral Adrenal Vein Sampling is Not Achieved.

  (Wang TS, Kline G, Yen TW, Yin Z, Liu Y, Rilling W, So B, Findling JW, Evans DB, Pasieka JL.) World J Surg. 2018 02;42(2):466-472.

• Excellence in the treatment of patients with pituitary tumors.

  (Molitch ME, Findling JW, Clemmons DR.) Pituitary. 2018 02;21(1):107.

• Diagnosis and management of adrenal insufficiency

  (He X, Findling JW, Auchus RJ.) Contemporary Endocrinology. 2018:199-215.

• Diagnosis and Differential Diagnosis of Cushing's Syndrome.

  (Findling JW, Nieman L, Tabarin A.) N Engl J Med. 2017 07 13;377(2):e3.

• DIAGNOSIS OF ENDOCRINE DISEASE: Differentiation of pathologic/neoplastic hypercortisolism (Cushing's syndrome) from physiologic/non-neoplastic hypercortisolism (formerly known as pseudo-Cushing's syndrome).

  (Findling JW, Raff H.) Eur J Endocrinol. 2017 May;176(5):R205-R216.

• Lower extremity insufficiency fractures: an underappreciated manifestation of endogenous Cushing's syndrome.

  (Poonuru S, Findling JW, Shaker JL.) Osteoporos Int. 2016 12;27(12):3645-3649.

• Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study.

  (Findling JW, Fleseriu M, Newell-Price J, Petersenn S, Pivonello R, Kandra A, Pedroncelli AM, Biller BM.) Endocrine. 2016 Nov;54(2):516-523.

• POSTSURGICAL RECURRENT CUSHING DISEASE: CLINICAL BENEFIT OF EARLY INTERVENTION IN PATIENTS WITH NORMAL URINARY FREE CORTISOL.

  (Carroll TB, Javorsky BR, Findling JW.) Endocr Pract. 2016 Oct;22(10):1216-1223.

• Response to comments on: Cosyntropin stimulation testing on postoperative day 1 allows for selective glucocorticoid replacement therapy following adrenalectomy for hypercortisolism: Results of a novel, multidisciplinary institutional protocol.

  (Ortiz DI, Findling JW, Carroll TB, Javorsky BR, Carr AA, Evans DB, Yen TW, Wang TS.) Surgery. 2016 07;160(1):249-250.